News
-
-
PRESS RELEASE
Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President
Carolyn Bonner appointed CFO of Medicus Pharma Ltd. succeeding Jim Quinlan due to health reasons. Bonner to lead financial and operational aspects of the company. Medicus advances clinical programs and expands pipeline -
-
PRESS RELEASE
Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Medicus Pharma Ltd. announces FDA Commissioner's national priority voucher application for Skinject (SKNJCT-003) D-MNA to non-invasively treat BCC aligning with public health priorities and rare-disease needs -
-
PRESS RELEASE
Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights
Medicus Pharma Ltd. announces financial results and advancements in clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist. Company highlights important corporate updates and collaborations -
-
PRESS RELEASE
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Medicus Pharma Ltd. expands SKNJCT-003 clinical study to the United Kingdom for global patient recruitment. Approvals received from U.K. regulatory bodies enabling pivotal study -
-
PRESS RELEASE
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome
Medicus Pharma collaborates with the Gorlin Syndrome Alliance to provide compassionate access to SKINJECT™, a novel therapy for Gorlin Syndrome patients. The initiative aims to collect real-world data and integrate patient insights for future development
